Driven by a skyrocketing demand for medical drugs and vaccines, the pharma is currently experiencing robust expansion. This consistent upsurge in the industry's performance is rooted in the unwavering necessity for its products, thereby insulating it from potential economic instability. Moreover, continuous technological advancements are acting as a catalyst in its evolution.
Given this backdrop, investors could consider buying fundamentally robust pharma stocks Pacira BioSciences, Inc. (PCRX), Eli Lilly and Company (LLY), Viatris Inc. (VTRS), and Zoetis Inc. (ZTS) for steady returns.
